301246.SZ
Hubei Hongyuan Pharmaceutical Technology Co., Ltd.
SZSE · C 制造业 · CN
CNY 20.84
−1.28%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.2B | 1.9B | 1.8B | 2.1B | 2.1B |
| Cost of Revenue | 1.7B | 1.6B | 1.6B | 1.8B | 1.6B |
| Gross Profit | 532.4M | 364.2M | 215.8M | 266.9M | 481.3M |
| Operating Expenses | |||||
| R&D Expense | 96.9M | 83.9M | 59.2M | 68.8M | 64.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 66.1M | 62.6M | 54.1M | 60.8M | 66.5M |
| Selling & Marketing Expense | 51.4M | 47.6M | 37.3M | 37.7M | 36.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 244.8M | 219.6M | 157.7M | 177.3M | 165.5M |
| Cost and Expenses | 1.9B | 1.8B | 1.7B | 2.0B | 1.7B |
| Operating Income (EBIT) | 329.6M | 158.3M | 60.0M | 105.6M | 479.9M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 298.8M | 145.7M | 59.7M | 98.6M | 478.0M |
| Income Tax Expense | 45.8M | 28.1M | 8.2M | 11.4M | 43.2M |
| Bottom Line | |||||
| Net Income | 254.5M | 119.1M | 51.5M | 87.2M | 434.8M |
| Earnings from Cont. Ops | 253.0M | 117.6M | 51.5M | 87.2M | 434.8M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 254.5M | 119.1M | 51.5M | 87.2M | 434.8M |
| Per Share | |||||
| Basic EPS | CN¥0.64 | CN¥0.30 | CN¥0.13 | CN¥0.22 | CN¥1.23 |
| Diluted EPS | CN¥0.64 | CN¥0.30 | CN¥0.13 | CN¥0.22 | CN¥1.23 |
| Revenue Per Share | CN¥5.57 | CN¥4.89 | CN¥4.44 | CN¥5.29 | CN¥5.85 |
| Shares | |||||
| Basic Shares Outstanding | 396.8M | 397.0M | 398.6M | 388.1M | 352.7M |
| Diluted Shares Outstanding | 396.8M | 397.0M | 398.6M | 388.1M | 352.7M |
| Profitability Metrics | |||||
| EBITDA | — | 362.5M | 241.1M | 266.2M | 575.2M |
| D&A | — | 204.2M | 181.1M | 160.6M | 95.2M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026